• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 2nd November 2017

OHE at ISPOR’s 20th Annual European Congress in Glasgow

Meet OHE researchers in Glasgow, where they’ll be presenting their work at ISPOR from 4th-8th November 2017 Next week, Glasgow will host the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress. OHE researchers will be in…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Meet OHE researchers in Glasgow, where they’ll be presenting their work at ISPOR from 4th-8th November 2017

Next week, Glasgow will host the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress. OHE researchers will be in attendance and presenting OHE research.

The theme for this year’s Congress is The Evolution of Value in Health Care; a subject central to many of OHE’s research projects. We’ll be participating in 11 different sessions across 4 days, on a variety of topics including MCDA, EQ-5D, orphan drugs, antibiotics, and societal preferences.

Here’s a run-through (in chronological order) of what we’re involved in. Come and see us at one of our sessions.

Sunday 5th November

  • 08:00-12:00: Risk-sharing / performance-based arrangements for drugs and other medical products.

With Lou Garrison and Josh Carlson of the University of Washington, Adrian Towse will be presenting on this intermediate-level short course. The course covers both theory and practice, including several examples of performance-based schemes from Europe, the United States, and Australia.

  • 13:00-17:00: Using multi-criteria decision analysis in health care decision making: approaches & applications.

With Maarten IJzerman and Kevin Marsh, Martina Garau will present on this short course. The course provides an introduction to MCDA for health care. Martina’s presentation will focus on the use of MCDA in HTA, by reviewing current uses of MCDA for HTA and the challenges they pose.

Monday 6th November

  • 12:45-13:45: PCN219: Is willingness to pay higher for cancer prevention and treatment?

This poster by Koonal Shah examines whether society is willing to pay more for cancer prevention and treatment than for other types of health care. It is based on a paper published in the Journal of Cancer Policy, which appeared in the ‘Value and Cancer’ special issue.

  • 15:45-16:45: W5: Sustainable funding and fair pricing for orphan drugs: what are the solutions?

Martina Garau will lead a discussion with Michael Drummond, Saskia Knies and Olivier Ponet. The purpose of the workshop is to discuss options to make paying for orphan drugs sustainable for healthcare systems, whilst providing a ‘fair’ reward to manufacturers investing in areas of high unmet need but small populations. Martina will start the session providing evidence on the rate of HTA approval and reimbursement of orphan drugs across Europe, building on earlier work.

  • 15:45-16:45: IP6: Are existing health technology assessment requirements inadequate for establishing value for potentially transformative gene therapies?

For this issue panel, Adrian Towse will share his perspective on approaches to evaluating the cost-effectiveness of gene therapies, considering the high up-front costs and potential longer-term and/or transformative benefits, building on work with the Institute for Clinical and Economic Review (ICER) and presented at the ICER Gene Therapy Summit.

Tuesday 7th November

  • 08:45-09:45: W10: EQ-5D: Is NICE ready for the next level?

Nancy Devlin (representing the EuroQol Research Foundation), Rosemary Lovett and Allan Wailoo will lead a discussion of why the EQ-5D-5L was developed, the evidence for its advantages over the EQ-5D-3L, and ongoing research into the characteristics of the valuation sets.

  • 14:00-15:00: IP12: What should patient-centred care mean in the welfare states of Europe? The United Kingdom and Germany cannot both be right.

Nancy Devlin joins Axel Mühlbacher for a panel discussion.

  • 15:30-16:30: IP13: MCDA valuation and ICERs – can they align for decision-making purposes?

Nancy Devlin will join this invited issue panel, which will debate and discuss the merits of approaches to comparing costs and benefits in the context of multi-criteria decision analysis (MCDA) models.

  • 18:15-19:15: PHP195: Valuing health at the end of life: an examination of framing effects and study design considerations.

This poster, presented by Koonal Shah, assesses whether any observed preferences regarding an end-of-life premium are affected by framing effects, such as whether or not visual aids and indifference options are included in the survey. The study used a six-arm design, with each arm applying a different framing.

Koonal Shah and Nancy Devlin are co-authors of two other posters in this session, which report findings from the EQ-5D-5L value set for Ireland study, led by researchers at NUI Galway. These posters will be presented by Luke Barry and Anna Hobbins. Patricia Cubi-Molla co-authors a poster titled ‘Patients acknowledge adaptation: the case of amputees’.

Wednesday 8th November

  • 10:00-11:00: IP22: How can we assess the value of new antibiotics?

Adrian Towse will present work from the OHE on developing a value framework for antibiotics, building on a recent Discussion Forum in London with key stakeholders.

  • 15:30-16:30: IP27: Valuing children’s HRQoL for health technology assessment: what are the issues and challenges?

Nancy Devlin will be moderating this issue panel.

  • Policy, Organisation and…
  • Presentations

Related News

  • News
  • March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Read more
  • News
  • March 2020

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Read more
  • News
  • January 2020

Funding Challenges in the Malaysian Health Care System

Read more
  • News
  • January 2020

OHE at HESG Winter 2020

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!